MRG003 plus gemcitabine for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called MRG003 combined with gemcitabine for people with advanced pancreatic cancer that has stopped responding to or cannot tolerate initial treatment. It aims to see if the combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced pancreatic cancer that has spread or cannot be removed by surgery.
- Your first chemotherapy stopped working or caused side effects you couldn't handle.
- You are able to get out of bed and take care of yourself (ECOG score 0-2).
- You are willing to provide a tumor sample (from a prior biopsy or a new one) for special testing.
- You have not been treated before with gemcitabine as your first therapy.
- You have not had a prior antibody-drug conjugate like MRG003.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests a new drug called MRG004A (plus best supportive care) against a placebo (plus best supportive care) for people with advanced pancreatic cancer who have already tried chemotherapy. The goal is to see if MRG004A can help shrink or slow the cancer.
This trial tests a new drug, LM-302, combined with gemcitabine for people with a specific type of advanced pancreatic cancer that has not responded to or stopped working on first-line treatment. The goal is to see if the combination is safe and effective.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.